General Information of DTT (ID: TT9V5JH)

DTT Name Phospholipase A2 (PLA2G1B) DTT Info
Gene Name PLA2G1B

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
5 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [1]
Clobetasol DMUXP52 Rosacea ED90.0 Approved [2]
Clocortolone DM9ZMQH Exanthem Approved [3]
Diflorasone DMI9PRJ Exanthem Approved [4]
Miltefosine DMND304 Chronic urticaria Approved [5]
------------------------------------------------------------------------------------
7 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
AllerB DM78DOT Allergy 4A80-4A85 Phase 2b [6]
MANOALIDE DMB4A8I Arthritis FA20 Phase 2 [7]
MRX-4 DMQZWYE Allergic rhinitis CA08.0 Phase 2 [8]
MRX-6 DMLVQKF Contact dermatitis EK0Z Phase 2 [9]
URSOLIC ACID DM4SOAW Metabolic syndrome x 5C50-5D2Z Phase 2 [10]
Varespladib DM5JJ83 Snakebite N.A. Phase 2 [11]
Rilapladib DMB9861 Arteriosclerosis BD40 Phase 1 [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Clinical Trial Drug(s)
8 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Darapladib DMSWLA3 Arteriosclerosis BD40 Discontinued in Phase 3 [13]
BMY-30129 DMA4UCP Pruritus EC90 Discontinued in Phase 2 [14]
EPC-K1 DMZKBU9 Nerve injury ND56.4 Discontinued in Phase 2 [15]
SC-106 DMTZ7E4 Rheumatoid arthritis FA20 Discontinued in Phase 2 [16]
WAY-123641 DMPE5XM Asthma CA23 Discontinued in Phase 2 [17]
PF-05212372 DMD83VY Asthma CA23 Discontinued in Phase 1 [18]
SB-435495 DM92BXN Arteriosclerosis BD40 Discontinued in Phase 1 [19]
YM-26734 DMEHAI2 Rheumatoid arthritis FA20 Terminated [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Discontinued Drug(s)
28 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-Methyl-2,4-Pentanediol DMD45CU Discovery agent N.A. Investigative [1]
3,9-dihydroxy-2,10-diprenylpterocap-6a-ene DMXZ8RJ Discovery agent N.A. Investigative [21]
4'-hydroxy-6,3',5'-triprenylisoflavonone DM7PWOL Discovery agent N.A. Investigative [21]
ABYSSINONE V DMH3CK2 Discovery agent N.A. Investigative [21]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [1]
AGN-190383 DM53R94 Discovery agent N.A. Investigative [22]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [1]
BM-162115 DMDNPML Inflammation 1A00-CA43.1 Investigative [23]
BOLINAQUINONE DMVB6UG Discovery agent N.A. Investigative [24]
CACOSPONGIONOLIDE DMIPJUS Discovery agent N.A. Investigative [25]
CACOSPONGIONOLIDE B DMCSXNW Discovery agent N.A. Investigative [25]
Cacospongionolide E DM2DYAV Discovery agent N.A. Investigative [25]
folipastatin DMEPZ2I Discovery agent N.A. Investigative [26]
HELENAQUINONE DM5MOLY Discovery agent N.A. Investigative [27]
Heptanoic Acid DM4NY9H Discovery agent N.A. Investigative [28]
Hexane-1,6-Diol DMWAPGI Discovery agent N.A. Investigative [1]
Hyrtiosulawesine DMWLJ5S Discovery agent N.A. Investigative [29]
Lpc-Ether DM1JGDM Discovery agent N.A. Investigative [1]
LY178002 DMI01YM Discovery agent N.A. Investigative [30]
LY256548 DM1KCHN Discovery agent N.A. Investigative [30]
Mepacrine DMU8L7C Discovery agent N.A. Investigative [31]
methylglyoxal DMRC3OZ Discovery agent N.A. Investigative [1]
N-Tridecanoic Acid DMNZ37C Discovery agent N.A. Investigative [28]
P-Anisic Acid DM8HWS9 Discovery agent N.A. Investigative [1]
Petrosaspongiolide M DMR8ZBT Discovery agent N.A. Investigative [32]
Petrosaspongiolide P DMMVZFN Discovery agent N.A. Investigative [33]
SB-203347 DM3AWMF Discovery agent N.A. Investigative [34]
WA-8242-A1 DMNRBDP Discovery agent N.A. Investigative [35]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 Investigative Drug(s)
Molecule Interaction Atlas

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
3 Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
4 Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
5 Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
6 Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
7 Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
8 Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
9 A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.
10 Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
11 Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. Toxins (Basel). 2022 Nov 11;14(11):783.
12 Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.J Am Coll Cardiol.2014 Jan 7-14;63(1):86-8.
13 Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease. IDrugs. 2009 Oct;12(10):648-55.
14 Inhibitor of phospholipase A2 blocks eicosanoid and platelet activating factor biosynthesis and has topical anti-inflammatory activity. J Pharmacol Exp Ther. 1994 Nov;271(2):852-9.
15 Posttreatment with EPC-K1, an inhibitor of lipid peroxidation and of phospholipase A2 activity, reduces functional deficits after global ischemia in rats. Brain Res Bull. 1995;36(3):257-60.
16 US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
17 Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. J Pharmacol Exp Ther. 1994 Feb;268(2):888-96.
18 Phagedena due to leishmaniasis. Immunologic and experimental studies. Ann Dermatol Syphiligr (Paris). 1976;103(1):23-30.
19 The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in Aspergillus fumigatus sensitized mice. Respir Res. 2012 Nov 12;13:100.
20 Simplified YM-26734 Inhibitors of Secreted Phospholipase A2 Group IIA
21 Phospholipase A2 Inhibitors from an Erythrina Species from Samoa J. Nat. Prod. 60(6):537-539 (1997).
22 AGN 190383, a novel phospholipase inhibitor with topical anti-inflammatory activity. Agents Actions. 1991 Sep;34(1-2):70-2.
23 Investigation on the effect of experimental phospholipase A2 inhibitors on the formyl-methionyl-leucyl-phenylalanine-stimulated chemotaxis of human leukocytes in vitro. Arzneimittelforschung. 1998 Jan;48(1):77-81.
24 New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5.
25 A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
26 Folipastatin, a new depsidone compound from Aspergillus unguis as an inhibitor of phospholipase A2.Taxonomy, fermentation, isolation, structure determination and biological properties.J Antibiot (Tokyo).1992 Aug;45(8):1195-201.
27 New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia. Bioorg Med Chem. 2010 Aug 15;18(16):6006-11.
28 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
29 Hyrtiazepine, an azepino-indole-type alkaloid from the Red Sea marine sponge Hyrtios erectus. J Nat Prod. 2006 Dec;69(12):1676-9.
30 The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2.
31 Involvement of protein kinase C activation in L-leucine-induced stimulation of protein synthesis in l6 myotubes. Cytotechnology. 2003 Nov;43(1-3):97-103.
32 Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffo... J Med Chem. 2007 May 3;50(9):2176-84.
33 Petrosaspongiolides M-R: new potent and selective phospholipase A2 inhibitors from the New Caledonian marine sponge Petrosaspongia nigra. J Nat Prod. 1998 May;61(5):571-5.
34 SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine... J Pharmacol Exp Ther. 1995 Sep;274(3):1254-62.
35 WA8242A1, A2 and B, novel secretary phospholipase A2 inhibitors produced by Streptomyces violaceusniger. III. Structure elucidation and total synth... J Antibiot (Tokyo). 1998 Jul;51(7):655-64.